804550-60-5

Basic information

• Product Name: Acetamide, 2-bromo-N-(2,3-difluorophenyl)-
• CAS NO: 804550-60-5
• Molecular Formula: C8H6BrF2NO
• Molecular Weight: 250.043
• Mol File: 804550-60-5.mol

Chemical Properties

• CAS DataBase Reference: Acetamide, 2-bromo-N-(2,3-difluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, 2-bromo-N-(2,3-difluorophenyl)-(804550-60-5)
• EPA Substance Registry System: Acetamide, 2-bromo-N-(2,3-difluorophenyl)-(804550-60-5)

Safety Data

• Hazardous Substances Data: 804550-60-5(Hazardous Substances Data)

Upstream product

• 4519-40-8 2,3-difluoroanilline 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 930779-52-5 tert-butyl 2-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}hydrazinecarboxylate 
• 786681-68-3 2-(4-amino-1H-pyrazol-1-yl)-N-(2,3-difluorophenyl)acetamide 
• 916483-53-9 N-(2,3-difluorophenyl)-2-{4-[(diphenylmethylene)amino]-1H-pyrazol-1-yl}acetamide 
• 1111269-32-9 C₁₇H₂₀BF₂N₃O₃ 
• 1111269-58-9 C₈H₆F₂N₄O 
• 930779-55-8 N-(2,3-difluorophenyl)-2-(4-{[(dimethylamino)methylene]amino}-1H-pyrazol-1-yl)acetamide 

Relevant articles and documents

Two new syntheses of a 4-aminopyrazole: Condensation of an N-substituted vinamidinium salt with a functionalized hydrazine

Two novel syntheses of a key 4-aminopyrazole synthetic building block are described. Both routes avoid the potentially explosive precursors that were used in the previously patented route. A salt of a vinamidinium cation previously used in 5-aminopyrimidi

QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS

The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for’ the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.

QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS

The invention provides named compounds of formula (I ), wherein R4 is a N- sustituted quinuclidine ( I ) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for' the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.

(3- ((QUINAZOLIN-4-YL) AMINO )-1H-PYRAZOL-1-YL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER

Quinazoline derivatives of formula (I) for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to processes for their preparation, as well as pharmaceutical compositions containing, them as active ingredient. X is O or NR 6 ;R 5 is aryl or heteroaryl optionally substituted by 1, 2 or 3 substituents independently selected from halo, hydroxy, cyano, nitro, amino,C 1-4 alkylamino, bis(C1-4 alkyl)amino, C 1-4 alkyl, C 2-4 alkenyl,C 2-4 alkynyl, C 1-4 alkoxy, C(O)NHR17 , NHC(0)R 18 and S(O) p R 19where p is 0,1 or 2;The other substituents are as defined in claim 1.